Announcement PDF Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 Australian Microcap Investment Conference presentation 11 May 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to provide the presentation to be delivered at the 15th Annual Australian Microcap Investment Conference, being held in Sydney, Australia on 11 May 2026. The presentation will be delivered by Chief Operating Officer, Mr John Clark, and forms part of Neurizon’s ongoing investor engagement activities aimed at increasing awareness of the Company’s clinical development programs, strategic progress and upcoming milestones among Australian and international investors. The Australian Microcap Investment Conference is one of Australia’s leading investment conferences focused on the microcap sector, bringing together members of the investment community to hear directly from ASX-listed companies with market capitalisations under A$300 million. Following its long-standing success in Melbourne, the conference has expanded to Sydney in 2026. The presentation provides an overview of Neurizon’s development activities for NUZ-001, including recent recruitment progress in the HEALEY ALS Platform Trial, operational execution, and upcoming clinical and corporate milestones. The presentation slides are attached to this announcement. -ENDS- This announcement has been authorised for release by Sergio Duchini, Interim Executive Chairman on behalf of the Board of Neurizon Therapeutics Limited. For any questions, comments, or further information regarding Neurizon, please email enquiries@neurizon.com, or contact: Marketing & Corporate Affairs Lidija Damjanovic Marketing & Corporate Affairs Email: lidija@neurizon.com Phone: +61 (0) 425 700 504 Investor Relations Henry Jordan Six Degrees Investor Relations Email: henry.jordan@sdir.com.au Phone: +61 (0) 431 271 538 Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction. Neurizon Investor Hub We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements. To access Neurizon Investor Hub please scan the QR code or visit https://investorhub.neurizon.com Neurizon® is a registered trademark of Neurizon Therapeutics Limited ABN 35 094 006 023 Neurizon Therapeutics John Clark, Chief Operating Officer Australian Microcap Investment Conference May 2026, Sydney A promising new horizon in neurodegenerative diseases Disclaimer This disclaimer applies to this presentation and the information contained in it (This presentation has been prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”)). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters. No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation. This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so). Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company. Australian Microcap Investment Conference 2 Future Matters This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. US Disclosure This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers. To lead the development of neurodegenerative treatments towards a promising new horizon for patients. Our Vision Accelerating Patient Access to Innovative ALS Treatment Our Promise Driving Clinical Progress Unlocking the potential of Neurizon to address high unmet need in neurodegenerative diseases Delivering commercial readiness and stakeholder value 5 Australian Microcap Investment Conference Neurizon: From Scientific Origin to Clinical Momentum A unique opportunity in neurodegenerative diseases Well characterised drug Disease-modifying potential Strong foundation Late-stage clinical execution 1 2 3 4 5 DISCOVERY & FOUNDATION CLINICAL VALIDATION & HEALEY SELECTION 2005 - 2013 TRANSLATION TO HUMAN DISEASE 2013 - 2021 NEURIZON FORMATION & STRATEGY 2022 - 2023 2024 - 2025 CLINICAL EXECUTION 2026 - 2027 Monepantel – a proven veterinary product with extensive safety and pharmacology data From veterinary use to potential in neurodegenerative diseases Building a focused clinical-stage company with the clear focus on neurodegenerative diseases NUZ-001 Phase 1 results show early signals of efficacy in a small study with people living with ALS/MND and drive inclusion into HEALEY trial Active execution of Registrational Phase 2/3 HEALEY ALS Platform Trial NUZ-001 is a well-characterised molecule, with novel neurodegenerative biology, and is now advancing through a registrational Phase 2/3 clinical program NUZ-001: Potential application to range of neurodegenerative diseases 6 TDP-43 ALS/AD/PD/FTD/CTE Amyloid beta AD/PD Tau AD/PD/FTD/CTE/PSP alpha Synuclein AD/PD NUZ-001 is a mechanism-driven, disease-agnostic approach to treating neurodegeneration by rebalancing proteostasis and addressing core cellular dysfunction. AD = Alzheimer’s Disease; ALS = Amyotrophic Lateral Sclerosis; CTE = Chronic Traumatic Encephalopathy; FTD = Frontotemporal Dementia; HD = Huntington Disease; PD = Parkinson’s Disease; PSP = Progressive Supranuclear Palsy ALS is a current priority, but NUZ-001 has potential application to a range of neurodegenerative diseases. mHTT HD Australian Microcap Investment Conference New preclinical data show NUZ-001 increases activity of multiple protein clearance pathways in neuronal models: autophagy and proteasomal systems. Phase 1 Access to manufacturing at scale critical to future commercialisation Access to animal safety data and manufacturing data critical to support future trials and potential regulatory approvals Strongly Positioned with Regulatory and Commercialisation Requirements for Realisation Derisked regulatory approval process Drug / Dosage Form NUZ-001 Oral Tablets NUZ-001 Liquid and Oral Tablets Phase 2/3 HEALEY ALS Platform Trial Phase 1 Amyotrophic Lateral Sclerosis (Motor Neurone Disease) HEALEY ALS Platform Trial Indication Preclinical Phase 2 Phase 3 Approved/ Marketed Potential for accelerated approval based on Phase 2/3 data Registrational adaptive Phase 2/3 clinical study 7 HEALEY Trial: Opportunity for accelerated approval Initial focus is ALS, a rare disease with high unmet need and the possibility of accelerated approval on Phase 2/3 data. Potential for broader application being developed through pre-clinical program. Australian Microcap Investment Conference NUZ-001 Preclinical Neurodegenerative Diseases Amyotrophic Lateral Sclerosis (Motor Neurone Disease) Phase 1 ALS MEND Study and Open Label Extension Early Signals of Efficacy -2.93 -1.65 -5 -4.5 -4 -3.5 -3 -2.5 -2 -1.5 -1 -0.5 0 PRO-ACT Matched Controls (n=420) NUZ-001 (n=12) Phase 1 Open Label Extension Preliminary Efficacy ALSFRS-R and SVC 9 Treatment with NUZ-001 across combined Phase 1 and OLE studies slowed the progression of ALS in all patients by 31% for ALSFRS-R and 43% for SVC percent predicted (PP) when compared to matched controls from the PRO-ACT historical database1 1. Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014 Nov 4;83(19):1719-25. doi: 10.1212/WNL.0000000000000951.Epub 2014 Oct 8. PMID: 25298304; PMCID: PMC4239834 2. Forced vital capacity (FVC) was used when SVC was not collected 3. Matched on time since onset, baseline ALSFRS-R, pre-baseline slope, and disease onset location Difference 1.27 points/month (p=0.078) 43% Respiration – SVC PP2 -1.21 -0.83 -2 -1.8 -1.6 -1.4 -1.2 -1 -0.8 -0.6 -0.4 -0.2 0 PRO-ACT Matched Controls (n=360) NUZ-001 (n=12) ALSFRS-R Slope (points/month) Motor Function – ALSFRS-R Difference 0.37 points/month (p=0.145) 31% 3 3 Australian Microcap Investment Conference VC PP Slope (points/month) Phase 1 Open Label Extension Survival Probability Analysis 10 Compared to matched controls from the PRO-ACT database, treatment with NUZ-001 results in significantly longer survival of patients with ALS (X2=10.95, p=0.00094) . Analysis Method Log-Rank Test Cox Proportional Hazards Model Dataset Death Time Imputation χ2 p-value Hazard Ratio 95% CI p-value Assumed Survival Leave out Last Visit 10.9 5 11.9 8 0.00094 0.00054 0.298 0.287 (0.135, 0.659) (0.131, 0.632) 0.0028 0.0019 Confirmed Survival Leave out Last Visit 16.6 7 18.4 3 0.00004 0.00002 0.266 0.254 (0.126, 0.561) (0.121, 0.534) 0.0005 0.0003 Hazard ratio of 0.298 (95% CI: (0.135, 0.659), p = 0.0028) suggests that treatment with NUZ-001 reduces the risk of death by 70.2% Australian Microcap Investment Conference 11 Phase 1 Open Label Extension Safety and Tolerability Summary Study drug was shown to be safe and generally well tolerated during long-term administration in the OLE, with no dose-limiting toxicities and no treatment-related deaths. • No participants withdrew from study • No serious adverse events related to study drug (Raised liver enzyme, Increased hair growth, Dry mouth at night) • No unexpected safety findings observed in the OLE compared with Phase 1 MEND • 3 patients still receiving treatment under the TGA’s Special Access Scheme Total (n) Related to Treatment (n) Adverse Events 25 3 Serious Adverse Events 5 0 Australian Microcap Investment Conference Registrational Phase 2/3 HEALEY ALS Platform Trial HEALEY ALS Platform Trial Regimen ‘I’ for NUZ-001 13 Inclusion/Exclusion Criteria 36-week Double Blind Placebo Controlled Period 36-week Active Treatment Extension Period 3:1 Randomisation n=160 participants Primary Endpoint • Change from baseline through Week 36 in disease severity, measured by the ALSFRS-R total score and survival Secondary Endpoints • Change from baseline through Week 36 in secondary efficacy measures (e.g., respiratory function via slow vital capacity (SVC)) • Survival through Week 36 (death or equivalent endpoint) NUZ-001 10 mg/kg Placebo NUZ-001 10 mg/kg Australian Microcap Investment Conference 14 ‘Regimen-I’ HEALEY ALS Platform Trial Expected Key Milestones Enrollment Complete Q3-Q4 2026 First Patient Dosed 160 patients enrolled in the trial First patient screened for eligibility Last Patient Dosed Q1 2026 First Patient Screened Q2-Q3 2027 Last participant receives final dose Database Lock Q3 2027 Clinical trial database locked for analysis Topline Data Released Topline results of the trial announced Q3 2027 First participant dosed in Regimen I Platform Trial IND submitted to regulatory authorities Q4 2025 IND Amendment Submission NUZ-001 entry accepted Q4 2025 FDA Clearance Q1 2026 5 6 7 8 Anticipated Trial Execution Updates Site Activation Confirmation of additional clinical sites opened and recruitment underway Enrolment Milestones Achieved Progress updates on patient recruitment (e.g., 50% enrolled, enrolment complete) Completion Milestones Last Patient In (LPI) and Last Patient Last Visit (LPLV), with timing guidance for topline data release Australian Microcap Investment Conference Strong Recruitment Momentum 59 62 123 48 15 Activated Sites Master Screening Dosed Participants Regimen Assignment Australian Microcap Investment Conference Numbers referred to above are as of 5 May 2026. Investment Potential Placement & Entitlement Offer • Raised ~A$7.1 million under the Placement, through issue of New Shares at A$0.08 per New Share for the HEALEY ALS Platform Trial • 2-for-5 Entitlement Offer at A$0.08 per New Share, which raised a total of A$8.5 million through the entitlement offer (January 2026) and the shortfall placement (April 2026). Research & Development (R&D) Tax Rebate • Neurizon’s Advance and Overseas Finding (AOF) provides a cash rebate for foreign R&D spend • Cash rebate of at least 43.5% on HEALEY spend • AOF is binding on Australian Tax Office and AusIndustry - providing an important, non- dilutive source of funds Convertible Note Facility • Convertible Note Facility for up to A$20 million with Obsidian Global GP, LLC • Initial draw of A$5 million completed in February 2026 • Committed facility - option but no obligation to use remaining A$15 million in the facility • Includes trading restrictions to protect shareholder and optionholder interests Neurizon’s funding strategy has been developed with a focus on protecting shareholders’ interests through flexible funding instruments and minimising dilution. This includes the ability to finance the company’s R&D rebate receivables and the ability to displace the convertible note facility, if appropriate to do so. 17 HEALEY: Funding secured Strong shareholder support has secured adequate funding for HEALEY ALS Platform trial1 1 See ASX: NUZ - Equity Raising Presentation (23 December 2025), including details of funding strategy and identified risks. Australian Microcap Investment Conference 18 ALS: High Unmet Need with Significant Value Potential A serious, rapidly progressive disease with limited treatment options. Meaningful innovation in ALS can create value for people living with ALS and the market. ~30,000+ people living with ALS in the U.S only.1 Rapid progression Median survival often 2–5 years from diagnosis² High unmet need Limited treatment options. Need remains for therapies addressing underlying disease biology. Aims to inhibit TDP- 43 aggregation and restore proteostasis (NUZ-001 mechanism of action). Addresses key ALS pathology Entered Phase 2/3 HEALEY ALS Platform Trial. Clinical- stage program Exploring relevance in other neurodegenerative diseases with shared pathology. Multi- Indication potential Convenient, scalable formulation with the potential for broad patient access. Oral administration NUZ-001 Investigational oral therapy Designed to address key disease biology in 97% of people living with ALS WHY NUZ-001 IS RELEVANT THE NEED IN ALS COMMERCIAL VALUE POTENTIAL ALS market has demonstrated significant strategic value Multiple large-value transactions and licensing deals in recent years. Strong interest in differentiated therapies, particularly with oral or disease-modifying potential. Appeared safe and generally well-tolerated with signals of efficacy in exploratory studies 1. The ALS Association; www.als.org; accessed April 2026 2. Chio A, et al Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10(5-6);310-323 Potential value drivers for Neurizon Regulatory milestones Partnership and licensing optionality Pipeline expansion into HD and other neurodegenerative diseases Australian Microcap Investment Conference ALS: High Unmet Need with Significant Value Potential Australian Microcap Investment Conference 19 Multiple large-value transactions and deals in recent years Key ALS Value Reference Point: Shionogi – RADICAVA US$2.5B Transaction (April 2026)1 Transaction: Shionogi acquired global rights to RADICAVA (IV edaravone) and RADICAVA ORS (oral edaravone) from Tanabe Pharma. Deal value: US$2.5 billion upfront (lump sum), with potential additional royalties on future sales (subject to conditions). Timing: Announced 22 December 2025 and completed in early April 2026 Asset profile: A commercial, revenue-generating ALS therapy franchise with both IV and oral formulations already in market. Strategic rationale: Strengthened Shionogi’s rare disease commercial platform (especially US), adding established programs/teams and readiness to launch additional rare disease treatments. Other Recent ALS Deals Eli Lilly entered neurodegenerative disease collaborations with Alchemab2 (2025; reported up to US$415M) and QurAlis3 (2024; US$45M upfront plus potential milestones). Eli Lilly and Verge Genomics4 entered an ALS discovery collaboration in 2021. Public reports described potential transaction economics of approximately US$694M. Ferrer: Prilenia and Ferrer announced a strategic collaboration and licensing agreement relating to pridopidine in 2025.5 1. Shionogi press release, 22 December 2025; transaction completion announced April 2026. 2. Alchemab Therapeutics press release, 6 May 2025 3. QurAlis press release, 3 June 2024 4. Fierce Biotech, 6 January 2021 5. Prilenia Therapeutics press release, 28 April 2025 2: mTOR pathway-related diseases NUZ-001: Strong portfolio protection 2035 2040 2030 2025 2015 2020 Patent Families for monepantel 1: Human kinase inhibitor 3: Combinatorial treatments 4: API repurposing protection 5: Neurodegenerative diseases What is protected: • Key analogues of monepantel • Optimised dosing, formulation and combo strategies • Monepantel use in neurodegenerative and mTOR-related diseases Protected Jurisdictions: 1. AU, CA, CN, EU, CH, HK, JP, SK, USA 2. AU, CA, CN, EU, CH, HK, JP, SK, USA 3. AU, CA, CN, EU, CH, HK, JP, SK, USA 4. AU, EU, CH, JP, USA 5. AU, USA; Pending: CA, EU, HK, JP 20 Australian Microcap Investment Conference In addition to patent protection, NUZ-001 has US Orphan Drug Designation (ODD) and European Orphan Medicinal Product Designation (OMPD) providing 7 and 10 years of market exclusivity, respectively. 21 FDA EMA PMDA Orphan Drug Designation Type C Meeting Q2 2024 Q3 2026 HEALEY Topline Results H2 2027 Orphan Drug Designation Q4 2024 Scientific Protocol Advice Meeting Q3 2026 General Consultation Q2 2026 ODD Application H2 2026 JNDA Application H2 2028 MAA Submission H1 2028 NDA Submission H1 2028   IND Clearance Q3 2025  NUZ-001 Regulatory Strategy for ALS Market Access Australian Microcap Investment Conference Demonstrating Meaningful Progress Successfully raised $7.1m through a share placement 22 Executed Global License Agreement with Elanco Regimen “I” commenced in the HEALEY ALS Platform Trial Successful manufacture of three registration batches of NUZ-001 Received ~$6m cash rebate from R&D Tax Incentive for FY2025 Promising exploratory top- line results from Phase 1 and OLE study R&D Tax Incentive Advance & Overseas Finding Approval Raised $5.88m through Entitlement Offer to Eligible Shareholders Australian Patent granted for NUZ-001 – Expiry 2041 Established a $20m strategic con note facility with Obsidian Secured registered trademark protection for NEURIZON® Australian Microcap Investment Conference Strengthened preclinical data and understanding of the MOA of NUZ-001 23 What Comes Next in Our Growth Strategy Australian Microcap Investment Conference Potential Value Outcomes: Our Focus Areas: Ongoing clinical execution Continued data generation Progressing the Regulatory Pathway Further strengthening of scientific insight Partnership expansion and opportunities Clinical de-risking driving higher probability of success High-quality data generating long-term value Sustainable value creation for shareholders Stronger partnerships creating scale and reach Regulatory progress unlocking future milestones and optionality Q&A Registered Address: Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000 Australia +61 (3) 9692 7222 enquiries@neurizon.com THANK YOU